Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART20.1 in Relapsed or Refractory CD20+ B-NHL
NCT03664635Phase 2Completed
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Sep 2018
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-CART20.1 in B-cell non-Hodgkin lymphoma, sponsored by Miltenyi Biomedicine GmbH. Started Sep 2018; status: completed.
02
Drugs
MB-CART20.1
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03664635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664635.